Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month, randomized, placebo-controlled, dose-response study. - Aronoff,S.; Rosenblatt,S.; Braithwaite,S.; Egan,J.W.; Mathisen,A.L.; Schneider,R.L, on behalf of the Pioglitazone 001 Study Group. (Diabetes Care, 2000)